Literature DB >> 8225591

Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I.

W A Flegel1, M W Baumstark, C Weinstock, A Berg, H Northoff.   

Abstract

Interaction of endotoxin (lipopolysaccharide [LPS]) with human lipoproteins is known to prevent the LPS-induced activation of human monocytes and release of cytokines (monokines). LPS was exposed to lipoprotein classes separated by ultracentrifugation and to apolipoprotein A-I. Then monocytes were added, and the LPS activation of monocytes was determined by measuring the induced monokines. Failure of LPS to induce monokine release was called LPS inactivation caused by lipoproteins or apolipoproteins. The LPS inactivation is shown to be a function of low-density lipoproteins. High-density lipoproteins inactivate LPS to a much lesser extent. The very-low-density lipoproteins cannot inactivate LPS. Lipid components seemed not absolutely required for LPS inactivation, because purified human apolipoprotein A-I without its physiological lipid complement also inhibits LPS-induced monokine release.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225591      PMCID: PMC281294          DOI: 10.1128/iai.61.12.5140-5146.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility.

Authors:  D J Roeder; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

2.  Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide.

Authors:  J M Cavaillon; C Fitting; N Haeffner-Cavaillon; S J Kirsch; H S Warren
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  A simple sensitive bioassay for interleukin-1 which is unresponsive to 10(3) U/ml of interleukin-2.

Authors:  A J Gearing; C R Bird; A Bristow; S Poole; R Thorpe
Journal:  J Immunol Methods       Date:  1987-05-04       Impact factor: 2.303

4.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.

Authors:  W A Flegel; A Wölpl; D N Männel; H Northoff
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein.

Authors:  P S Tobias; K Soldau; R J Ulevitch
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

6.  A purification method for apolipoprotein A-I and A-II.

Authors:  M C Peitsch; A Kress; P G Lerch; J J Morgenthaler; H Isliker; H J Heiniger
Journal:  Anal Biochem       Date:  1989-05-01       Impact factor: 3.365

7.  The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide.

Authors:  B J Van Lenten; A M Fogelman; M E Haberland; P A Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  Control of endotoxin activity and interleukin-1 production through regulation of lipopolysaccharide-lipoprotein binding by a macrophage factor.

Authors:  H S Warren; G R Riveau; F A de Deckker; L A Chedid
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

9.  Structural and physicochemical requirements of endotoxins for the activation of arachidonic acid metabolism in mouse peritoneal macrophages in vitro.

Authors:  T Lüderitz; K Brandenburg; U Seydel; A Roth; C Galanos; E T Rietschel
Journal:  Eur J Biochem       Date:  1989-01-15

10.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

View more
  42 in total

1.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein.

Authors:  M M Wurfel; E Hailman; S D Wright
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

3.  Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.

Authors:  Baomei Shao; Robert S Munford; Richard Kitchens; Alan W Varley
Journal:  Innate Immun       Date:  2012-03-22       Impact factor: 2.680

4.  Neuroinflammation Alters Integrative Properties of Rat Hippocampal Pyramidal Cells.

Authors:  Federica Frigerio; Corey Flynn; Ye Han; Kyle Lyman; Joaquin N Lugo; Teresa Ravizza; Antoine Ghestem; Julika Pitsch; Albert Becker; Anne E Anderson; Annamaria Vezzani; Dane Chetkovich; Christophe Bernard
Journal:  Mol Neurobiol       Date:  2018-02-09       Impact factor: 5.590

5.  Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  N Hiki; D Berger; C Prigl; E Boelke; H Wiedeck; M Seidelmann; L Staib; M Kaminishi; T Oohara; H G Beger
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia.

Authors:  T Kirikae; M Hirata; H Yamasu; F Kirikae; H Tamura; F Kayama; K Nakatsuka; T Yokochi; M Nakano
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

7.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.

Authors:  Sylvette Bas; Richard W James; Cem Gabay
Journal:  BMC Immunol       Date:  2010-09-16       Impact factor: 3.615

Review 9.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs.

Authors:  Ariadne Androulidaki; Dimitrios Iliopoulos; Alicia Arranz; Christina Doxaki; Steffen Schworer; Vassiliki Zacharioudaki; Andrew N Margioris; Philip N Tsichlis; Christos Tsatsanis
Journal:  Immunity       Date:  2009-08-21       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.